The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 4 May 2026•Updated 6 May 2026•

1 min read

Eli Lilly and Amgen Boost U.S. Manufacturing with Massive Capital Investments

Key Facts

1Amgen announced an additional $300 million investment in Puerto Rico to expand its U.S. manufacturing network.

The U.S. biotech sector is witnessing a significant investment surge as Eli Lilly announced an additional $4.5 billion commitment to expand two manufacturing sites in Indiana. This new investment brings the company's total capital expansion commitments in the state to more than $21 billion since 2020, highlighting a massive push for domestic production. Simultaneously, Amgen has allocated an additional $300 million to expand its manufacturing network in Puerto Rico to bolster supply chain resilience. These strategic moves are designed to meet rising global demand for innovative pharmaceuticals and modernize industrial infrastructure. Such substantial capital expenditures underscore management's confidence in long-term growth prospects across the industry. This collective momentum serves as a strong signal to investors regarding the sector's commitment to organic growth and large-scale asset development.

28 days ago

Version History

Version 128 days ago

What changed: The story was updated to include a massive $4.5 billion investment by Eli Lilly in Indiana, shifting the focus from a single Amgen investment to a broader sector-wide trend.